<div id="readability-page-1"><p>Aardvark Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst on May 15. Analyst Tazeen Ahmad from Bank of America Securities downgraded the rating on the stock to a Sell and gave it a $4.00 price target.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Tazeen Ahmad has given his Sell rating due to a combination of factors centered on the FDA’s clinical hold of Aardvark Therapeutics’ lead program, ARD-101, and the resulting uncertainty around development timelines. The company has halted trials after cardiac issues were observed at higher doses in healthy volunteers, and although management is in active dialogue with the FDA and plans to unblind phase 3 HERO and extension data in Prader-Willi syndrome, no firm schedule has been communicated.</p> <p>Ahmad also sees added risk from a changing regulatory environment and intensifying competition from products like Soleno’s Vykat XR and Rhythm’s setmelanotide, which could erode AARD’s future market opportunity. Reflecting these concerns, she lowers the probability of success and delays the assumed launch for the PWS program, removes value previously assigned to other indications and terminal growth, and raises discount rates, which collectively reduce her price objective from $18 to $4, supporting a Sell stance.</p> <p>In another report released on May 15, Morgan Stanley also downgraded the stock to a Sell with a $3.00 price target.</p></div>

AARD

<p>Aardvark Therapeutics, Inc. was downgraded by Bank of America analyst Tazeen Ahmad to a Sell rating with a price target slashed from $18 to $4. The downgrade follows an FDA clinical hold on its lead program, ARD-101, due to cardiac issues, and increased competition from other products. Morgan Stanley also downgraded the stock to Sell with a $3.00 target.</p>

Tip Ranks

Aardvark Therapeutics

Bank of America

Soleno Therapeutics

Rhythm Pharma

Morgan Stanley

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4